Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix's GeneStrat Includes ROS1 and RET Mutations

Biodesix has broadened its GeneStrat liquid biopsy test to include ROS1 and RET mutations in addition to EGFR sensitizing, EGFR resistance, KRAS, BRAF, and EML4-ALK alterations.

GeneStrat is a part of the Biodesix's larger "Lung Reflex" multi-omic liquid biopsy testing strategy, which also includes the VeriStrat proteomic testing. With results available within 72 hours, the company says that GeneStrat and VeriStrat together deliver comprehensive information for physicians to support critical treatment decisions at initial diagnosis, expediting appropriate treatment.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.